Antibody
Antibody boosts platelets, shows ‘rapid and sustained efficacy’ in immune thrombocytopenia
Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.
Positive phase 3 results for psoriasis antibody injection support NDA submission in China
A new antibody injection for the treatment of moderate to severe plaque psoriasis met all primary and key secondary endpoints in a phase 3 Chinese study, Innovent Biologics announced in a release.
Patients with IPF experience similar 48-week FVC declines with pamrevlumab, placebo
SAN DIEGO — The absolute change in FVC at 48 weeks was similar between patients with idiopathic pulmonary fibrosis receiving pamrevlumab vs. placebo, according to a presentation at the American Thoracic Society International Conference.
Treating psoriasis with biologics does not negatively affect COVID antibody production
The use of biologics to treat psoriasis does not affect antibody production after a patient has had a COVID infection or vaccination, according to a study.
Prothena to receive $55M from Bristol Myers Squibb for rights to anti-tau antibody
Prothena Corporation plc announced Bristol Myers Squibb exercised its option under its global neuroscience research and development collaboration to obtain exclusive worldwide commercial rights for PRX005, paying Prothena $55 million.
Shorter sleep duration associated with reduced antibody response to vaccination
People who slept less than 6 hours per night had lower antibody responses to hepatitis and influenza vaccinations compared with those who slept 7 to 9 hours, according to researchers.
Anti-MTBR tau antibody treatment for Alzheimer’s safe, well-tolerated, in phase 1 study
Prothena Corp. reported positive topline results from its phase 1 single ascending dose study of PRX005, an investigational tri-epitopic antibody for treatment of Alzheimer’s disease.
Mucosal vaccines for COVID-19 ‘should be developed and tested’
Experts argued for the development of COVID-19 vaccines that can be delivered at the site of infection, but questioned whether it is possible to make a mucosal vaccine that prevents SARS-CoV-2 infection — and not just severe disease.
Split dosing of COVID-19 vaccines provides antibody responses
Split doses of COVID-19 vaccines were able to provide antibody responsiveness among patients with allergic reactions to previous doses, according to a letter published in Annals of Allergy, Asthma & Immunology.
VIDEO: EGFR antibody recommended for first-line treatment of certain colorectal cancers
In this video, Smitha S. Krishnamurthi, MD, discussed the results of the STRATEGIC-1 trial, which she said validates a common initial treatment strategy for patients with RAS and BRAF wild-type metastatic colorectal cancer.